RT Journal Article
SR Electronic
T1 Impaired T cell functions along with elevated activated Tregs at the early stage of asymptomatic SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.25.20108852
DO 10.1101/2020.05.25.20108852
A1 Jingyi Yang
A1 Ejuan Zhang
A1 Maohua Zhong
A1 Qingyu Yang
A1 Ke Hong
A1 Ting Shu
A1 Dihan Zhou
A1 Jie Xiang
A1 Jianbo Xia
A1 Xi Zhou
A1 Dingyu Zhang
A1 Chaolin Huang
A1 You Shang
A1 Huimin Yan
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.25.20108852.abstract
AB Background Limited data are available on the T cell responses for the asymptomatic SARS-CoV-2 infection case.Methods An imported SARS-CoV-2 infection case in Wuhan was admitted in hospital for quarantine and observation. The T cell responses were followed up by flow cytometry analysis of the peripheral blood nonnuclear cells (PBMCs) at days 7, 13, 22, and 28 after admission.Findings We found the imported SARS-CoV-2 infection in Wuhan is an asymptomatic case. His T cell differentiation, proliferation and activation matched the classical kinetics of T cell responses induced by viral infection, but the activation maintained at a relatively low level. Function analysis indicated frequencies of IFN-γ producing CD4+ and CD8+ T cells were notably lower than that of the healthy controls (HC) at day 7, and then rebound gradually. But IFN-γ+CD8+ T cells were detained at a significant lower level even at day 28, when the SARS-CoV-2 virus had already become undetectable for 3 weeks. Moreover, percentage of IL-17 producing CD4+ T cells was also detained constantly at a much lower level compared to HC. At day 7, although percentage of Tregs was in normal range, the frequency of activated Treg (aTreg) was remarkably as high as 4·4-fold of that in HC.Interpretation The T cell activation in the asymptomatic SARS-CoV-2 infection experienced a significant suppression and presented impairment of Th1/Th17 and CD8+ T cell functions. Early elevation of the aTregs might play role in the activation and function of T cells in the asymptomatic SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Medical Ethical Committee of Wuhan Jinyintan hospital (approval number KY-2020-47.01).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe can offer the data.